… efficacy and safety of molnupiravir in patients with COVID-19. … for ongoing study of molnupiravir
in COVID-19 in USA and … results of studies conducted with molnupiravir in COVID-19. …

… of treatment with molnupiravir started … Covid-19 and at least one risk factor for severe
Covid-19 illness. Participants in the trial were randomly assigned to receive 800 mg of molnupiravir …

… the safety and efficacy of the molnupiravir administration in the treatment of patients with …
in the future to confirm the therapeutic effects of molnupiravir in patients with COVID-19. …

… Molnupiravir recently granted the FDA emergency use authorization to treat mild to moderate
COVID-19 patients … the mechanism of Molnupiravir-induced COVID-19 mutagenesis. This …

… may only be effective in some subgroups of hospitalized patients; therefore, publication of …
supports the use of molnupiravir in non-hospitalized patients with COVID-19. Further research …

… and antiviral activity of molnupiravir dosed twice-daily for 5 days in the treatment of patients
with mild to moderate COVID-19. Hypotheses included that molnupiravir would decrease the …

… molnupiravir in patients hospitalized with Covid-19. … potential of molnupiravir as an antiviral
treatment for Covid-19 is … 9 , 10 ) and the other in hospitalized patients (MOVe-IN trial). In this …

… Evidence from clinical studies showed that Molnupiravir caused significant reduction in
the risk of hospitalization or death in high-risk mild COVID-19 patients. Molnupiravir was also …

… the clinical benefits of molnupiravir use for nonhospitalized patients with COVID-19. However,
molnupiravir did not help to improve the clinical outcomes of hospitalized patients. These …

… molnupiravir in the enrolled patients was generally acceptable, with only 11.88% of
molnupiravir … Moreover, rapid initiation of molnupiravir within 1 day of COVID-19 onset was an …